« Previous Next » Gastroenterology
Volume 136, Issue 4 , Pages 1206-1214 , April 2009

Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection

Mary Y. Hu
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Kianoosh Katchar
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Lorraine Kyne
- Department of Medicine for the Older Person, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
Seema Maroo
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Sanjeev Tummala
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Valley Dreisbach
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Hua Xu
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Daniel A. Leffler
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
Ciarán P. Kelly
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- Reprint requests Address requests for reprints to: Ciarán P. Kelly, MD, Associate Professor of Medicine, Harvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Dana 601, Boston, Massachusetts 02215. fax: 617-667-8144

Received 9 June 2008 ,Accepted 11 December 2008.

(A) Receiver operating characteristic curves for the clinical prediction model of recurrent C difficile infection. The area under the curve for the derivation cohort was 0.83 (95% CI: 0.70–0.95), and

(A) Receiver operating characteristic curves for the clinical prediction model of recurrent C difficile infection. The area under the curve for the derivation cohort was 0.83 (95% CI: 0.70–0.95), and the area-under-the-curve for the validation cohort was 0.80 (95% CI: 0.67–0.92). The dashed line represents a test of no discrimination. (B) Receiver operating characteristic curves for the combined prediction model of recurrent C difficile infection. The area under the curve for the derivation cohort was 0.89 (95% CI: 0.80–0.99), and the area under the curve for the validation cohort was 0.62 (95% CI: 0.44–0.80). The dashed line represents a test of no discrimination.
- Full-Size Image
- Download to PowerPoint

Conflicts of interest The authors disclose the following: During the past 2 years, Ciarán P. Kelly has acted as a scientific consultant for Acambis, Actelion, BioHelix, Genzyme, Replidyne, Salix, and ViroPharm and has received research grant funding from Actelion Inc, Genzyme Inc, Massachusetts Biologics Laboratories, Medarex Inc, and Salix Pharmaceuticals, companies that are producing or developing treatments for C difficile infection. No potential conflicts of interest exist for other authors.

Funding Supported by grants from the National Institutes of Health (RO-1 AI053069 (to C.P.K.); K30-HL04095 for the Scholars in Clinical Science Program at Harvard Medical School (in which Mary Y. Hu was enrolled); and T32-DK0776 (to S.M. and D.A.L.); and the Irish Health Research Board (RP/2005/72, to L.K.).

PII: S0016-5085(08)02262-2

doi: 10.1053/j.gastro.2008.12.038

« Previous Next » Gastroenterology
Volume 136, Issue 4 , Pages 1206-1214 , April 2009